. 2015 Dec 23;18(4):378–385. doi: 10.4048/jbc.2015.18.4.378

Table 4. Risk of some site specific second cancer related to HER2 status adjusted by age and calendar year at diagnosis of the primary breast cancer^*.

	Cases	OR	95% CI	p-value
Lung	15	1.28	0.10-17.8	0.853
Skin (not melanoma)	46	2.86	0.64-12.7	0.167
Digestive system^†	55	3.64	1.36-9.79	0.010
Genital system^‡	42	3.12	0.83-11.7	0.092
Urinary system^§	16	3.60	0.12-653	0.629
Thyroid	11	9.70	0.70-135	0.090
Hematological^∥	29	2.22	0.17-28.7	0.542
Contralateral BC	69	1.43	0.50-4.06	0.501

HER2 =human epidermal growth factor receptor 2; OR =odds ratio; CI=confidence interval; BC=breast cancer.

^*Case control 1:5 matched by age group, stage, year of diagnosis of primary breast cancer, using risk set sampling; Multiple conditional logistic regression where the factors were adjusted by age and calendar year of diagnosis of primary breast cancer; ^†Digestive system: esophagus, stomach, small intestine, colon, rectum, liver and pancreas; ^‡Genital system: cervix and corpus uteri, ovary, other female genital organs; ^§Urinary system: kidney and bladder; ^∥Hematological: Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia Hodgkin and, non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute and chronic myeloid leukemia, acute monocytic leukemia, myeloma, myeloproliferative and myelodysplastic syndrome.

Table 4. Risk of some site specific second cancer related to HER2 status adjusted by age and calendar year at diagnosis of the primary breast cancer*.

Table 4. Risk of some site specific second cancer related to HER2 status adjusted by age and calendar year at diagnosis of the primary breast cancer^*.